AMP 2021 Digital Experience

Illumina will be presenting two talks at this year's AMP Digital Experience:

A preview of TruSight™ Oncology Comprehensive (EU):
Illumina’s in-development European Comprehensive Genomic Profiling test kit, based on DNA and RNA content.

Thursday Nov 18 3 pm EST

Join this preview session, Illumina’s Chief Medical Officer, Dr. Phil Febbo, and Vice President of Global Marketing, Kevin Keegan, will provide an overview of the upcoming European in-vitro diagnostic test for Comprehensive Genomic Profiling (CGP), TruSight Oncology Comprehensive (EU).

Topics include:

• How this CGP test is designed to help maximize the actionable information needed to inform the appropriate targeted therapies and trials for cancer patients, according to guidelines.
• How this CGP test will enable consolidation from multiple independent or small panel tests into one test, one workflow and one report
• How this kitted, and distributable CGP solution, with a sample-to-answer workflow, can empower laboratories in Europe to bring the test in-house, for closer access to patients and faster turnaround times to results.

Phil Febbo, MD
Chief Medical Officer
Illumina

Kevin Keegan
Vice President of Global Marketing
Illumina

Implementing Comprehensive Genomic Profiling in-house from a pathologist and an oncologist point of view

On-demand from start of conference

Comprehensive Genomic profiling (CGP) is becoming the standard of care in oncology. It allows clinicians to maximize clinical information from limited biopsy samples so that patients are matched with approved therapies or enrolled in relevant clinical trials.

In this workshop, a pathologist and an oncologist will discuss the impact of implementing CGP assay at their institution. They will describe how they collaborate and examine how local access to an expert to manage sample yields, expedite access to results, and assist with genomic data interpretation was instrumental to improved patient care and outcomes. They will discuss a few clinical cases to highlight the value of in-house comprehensive CGP assays.

Learn:

• Reasons to implement and value of a flexible future-proof DNA+RNA CGP in-house assay.
• The impact of reflex CGP testing settings on testing decision trees and workflow consolidation.
• Value of sample management and genomic literacy for oncologists and molecular tumor boards.

Wei Song, B.M., Ph.D.
Director, Clinical Genomic Laboratory
Director, Division of Molecular and Genomic Pathology
Assistant Professor of Pathology and Laboratory Medicine
Weill Cornell Medicine

Ashish Saxena, MD, PhD
Assistant Professor of Medicine
Department of Medicine
Division of Hematology & Medical Oncology
Thoracic Oncology Service
Weill Cornell Medicine

Prithwish Pal, PhD, MBA
Associate Director
Global Medical Affairs (Oncology)
Illumina